The following compounds are currently open for out licensing and/or co-development with a strategic partner:
Pritelivir - The perfect solution for resistant HSV infections at immunocompromised patients.
AIC649 - Proprietary Immune Modulator and Potential Cure for Chronic Hepatitis B Infection
If you have further questions please contact us